ADCT
ADC Therapeutics SA
$1.09
-$0.02(-1.80%)
33
Overall
40
Value
18
Tech
42
Quality
Market Cap
$126.72M
Volume
1.73M
52W Range
$0.78 - $4.98
Target Price
$5.00
Order:
Income Statement
| Metric | Trend | Chart | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||
| Total Revenue | $-246.3M | $33.9M | $74.9M | $69.6M | $70.8M | $81.4M | ||
| Total Revenue | $-246.3M | $33.9M | $209.9M | $69.6M | $70.8M | $81.4M | ||
| COST OF GOODS SOLD | ||||||||
| Cost of Revenue | -- | $1.4M | $3.3M | $2.5M | $5.9M | $5.8M | ||
| GROSS PROFIT | ||||||||
| Gross Profit | $-246.3M | $32.5M | $206.6M | $67.0M | $64.9M | $75.6M | ||
| OPERATING EXPENSES | ||||||||
| Operating Expenses | $219.3M | $294.2M | $330.0M | $233.0M | $195.5M | $183.9M | ||
| Research & Development | $142.0M | $158.0M | $186.5M | $127.1M | $109.6M | $104.0M | ||
| Research Expense | $142.0M | $158.0M | $186.5M | $127.1M | $109.6M | $104.0M | ||
| Selling, General & Administrative | $77.2M | $136.2M | $143.5M | $105.9M | $85.9M | $79.9M | ||
| Selling & Marketing Expenses | $22.1M | $64.8M | $69.1M | $57.5M | $44.0M | $43.4M | ||
| General & Administrative Expenses | $55.1M | $71.5M | $74.4M | $48.4M | $41.9M | $36.6M | ||
| Depreciation & Amortization | $4.9M | -- | -- | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | $235.5M | $201.5M | -- | ||
| OPERATING INCOME | ||||||||
| Operating income | $-219.3M | $-261.7M | $-123.3M | $-166.0M | $-130.7M | $-121.5M | ||
| EBITDA | $-246.0M | $-251.4M | $-105.6M | $-132.1M | $-75.1M | $-57.1M | ||
| NON-OPERATING ITEMS | ||||||||
| Interest Expense (Non-Operating) | -- | -- | $36.7M | $46.3M | $50.2M | $51.6M | ||
| Interest Income Operating | -- | $-230.0M | -- | -- | -- | -- | ||
| Intinc | $832.0K | $66.0K | $2.6M | $10.5M | $12.3M | $8.8M | ||
| Net Non-Operating Interest Income/Expense | $832.0K | $66.0K | $-34.2M | $-35.8M | $-37.9M | $-42.8M | ||
| Gain on Sale of Securities | -- | -- | $25.6M | -- | -- | -- | ||
| Other Income/Expense | $291.7M | $230.0M | $-135.6M | $-824.0K | $-10.9M | $-22.7M | ||
| Other Special Charges | -- | -- | $145.7M | $6.4M | $12.5M | $22.7M | ||
| SPECIAL ITEMS | ||||||||
| Restructring And Mn A Income | $4.9M | -- | -- | -- | -- | $13.1M | ||
| Special Income Charges | $-4.9M | -- | -- | -- | -- | $-13.1M | ||
| PRE-TAX INCOME | ||||||||
| EBIT | $-246.0M | $-251.5M | $-120.2M | $-154.6M | $-107.5M | $-90.0M | ||
| Pre-Tax Income | $-246.0M | $-251.5M | $-146.8M | $-195.4M | $-156.1M | $-141.6M | ||
| INCOME TAX | ||||||||
| Tax Provision | $327.0K | $-21.5M | $227.0K | $39.1M | $166.0K | $1.0M | ||
| NET INCOME | ||||||||
| Net Income | $-246.3M | $-230.0M | $-157.1M | $-240.1M | $-157.8M | $-142.6M | ||
| Net Income (Continuing Operations) | $-246.3M | $-230.0M | $-157.1M | $-240.1M | $-157.8M | $-142.6M | ||
| Net Income (Discontinued Operations) | $-246.3M | $-230.0M | $-157.1M | $-240.1M | $-157.8M | $-142.6M | ||
| Net Income (Common Stockholders) | $-246.3M | $-230.0M | $-157.1M | $-240.1M | $-157.8M | $-142.6M | ||
| Normalized Income | $-189.4M | $-24.6M | $-116.0M | $-154.4M | -- | $-127.1M | ||
| TOTALS | ||||||||
| Total Expenses | $219.3M | $295.6M | $333.3M | $235.5M | $201.5M | $189.7M | ||
| SHARE & EPS DATA | ||||||||
| Average Shares Outstanding | $65.3M | $76.7M | $78.3M | $81.7M | $97.2M | $127.1M | ||
| Average Shares Outstanding (Diluted) | $65.3M | $76.7M | $78.3M | $81.7M | $97.2M | $127.1M | ||
| Shares Outstanding | $76.7M | $76.8M | $80.6M | $82.5M | $99.1M | $127.0M | ||
| Basic EPS | $-3.77 | $-3 | $-1.99 | $-2.94 | $-1.62 | $-1.12 | ||
| Basic EPS (Continuing Operations) | $-3.77 | $-3 | $-1.99 | $-2.94 | $-1.62 | $-1.12 | ||
| Diluted EPS | $-3.77 | $-3 | $-1.99 | $-2.94 | $-1.62 | $-1.12 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | $-2.94 | $-1.62 | $-1.12 | ||
| OTHER METRICS | ||||||||
| Acquired In Process Rn D Income | $-246.3M | -- | -- | -- | -- | -- | ||
| Depletion | $4.9M | -- | -- | -- | -- | -- | ||
| Diluted Discontinuous Operations | -- | $-3 | $-1.99 | -- | -- | -- | ||
| Earnings from equity interest | -- | -- | $-10.1M | $-5.5M | $-1.5M | -- | ||
| Earnings From Equity Interest Net Of Tax | -- | -- | $-10.1M | $-5.5M | $-1.5M | -- | ||
| Loss And Loss Adjustment Expected Incurred | -- | $18.3M | -- | -- | -- | -- | ||
| Other Gand A | $55.1M | $71.5M | $74.4M | $48.4M | $41.9M | $36.6M | ||
| Other Write Down | -- | -- | $36.9M | -- | -- | -- | ||
| Selling Expense | $22.1M | $64.8M | $69.1M | -- | -- | -- | ||
| Restruct | $4.9M | -- | -- | -- | -- | $13.1M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ADCT | $1.09 | -1.8% | 1.73M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |